tiprankstipranks
Arvinas Holding Company (ARVN)
NASDAQ:ARVN
US Market
ARVN
Arvinas Holding Company
RESEARCH TOOLSreports
Want to see ARVN full AI Analyst Report?

Arvinas Holding Company (ARVN) Stock Forecast & Price Target

1,056 Followers
See the Price Targets and Ratings of:

ARVN Analyst Ratings

Moderate Buy
16Ratings
Moderate Buy
9 Buy
6 Hold
1 Sell
Based on 16 analysts giving stock ratings to
Arvinas
Holding Company
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ARVN Stock 12 Month Forecast

Average Price Target

$15.64
▲(42.21% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Arvinas Holding Company in the last 3 months. The average price target is $15.64 with a high forecast of $24.00 and a low forecast of $6.00. The average price target represents a 42.21% change from the last price of $11.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","10":"$10","15":"$15","20":"$20","25":"$25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.642857142857144,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,10,15,20,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.51,11.547692307692307,12.585384615384616,13.623076923076923,14.66076923076923,15.698461538461538,16.736153846153847,17.773846153846154,18.81153846153846,19.84923076923077,20.886923076923075,21.924615384615386,22.96230769230769,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.51,10.904835164835164,11.29967032967033,11.694505494505496,12.08934065934066,12.484175824175825,12.87901098901099,13.273846153846154,13.668681318681319,14.063516483516484,14.458351648351648,14.853186813186813,15.24802197802198,{"y":15.642857142857144,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.51,10.163076923076924,9.816153846153846,9.46923076923077,9.122307692307693,8.775384615384615,8.428461538461539,8.081538461538461,7.734615384615385,7.387692307692308,7.0407692307692304,6.693846153846154,6.346923076923077,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.23,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.33,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.14,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.81,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.86,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.83,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.39,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.33,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.51,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$24.00Average Price Target$15.64Lowest Price Target$6.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on ARVN
Etzer Darout
Barclays
Barclays
$18→$20
Buy
81.82%
Upside
Assigned
05/13/26
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (NASDAQ: ARVN), Sarepta Therapeutics (NASDAQ: SRPT) and Surgery Partners (NASDAQ: SGRY)
H.C. Wainwright Analyst forecast on ARVN
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$18
Buy
63.64%
Upside
Reiterated
05/13/26
Arvinas Buy Rating Reiterated as Analyst Highlights Pipeline Optionality and VEPPANU Deal, Maintains $18 Price Target
Wells Fargo Analyst forecast on ARVN
Derek Archila
Wells Fargo
Wells Fargo
$15
Buy
36.36%
Upside
Assigned
05/13/26
Arvinas Holding Company (ARVN) Receives a Buy from Wells Fargo
Wedbush Analyst forecast on ARVN
Robert Driscoll
Wedbush
Wedbush
$11
Hold
0.00%
Upside
Reiterated
05/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (NYSE: DOCS), Arvinas Holding Company (NASDAQ: ARVN) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)
BTIG Analyst forecast on ARVN
Jeet Mukherjee
BTIG
BTIG
$16→$18
Buy
63.64%
Upside
Reiterated
05/13/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sionna Therapeutics, Inc. (NASDAQ: SION), Verrica Pharmaceuticals (NASDAQ: VRCA) and Arvinas Holding Company (NASDAQ: ARVN)
TD Cowen Analyst forecast on ARVN
Tyler Van Buren
TD Cowen
TD Cowen
―
Hold
―
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (NASDAQ: ARVN) and Sensus Healthcare (NASDAQ: SRTS)
Goldman Sachs Analyst forecast on ARVN
Paul Choi
Goldman Sachs
Goldman Sachs
$6
Sell
-45.45%
Downside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Ovid Therapeutics (NASDAQ: OVID) and Arvinas Holding Company (NASDAQ: ARVN)
Guggenheim Analyst forecast on ARVN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$15
Buy
36.36%
Upside
Reiterated
05/01/26
Guggenheim Remains a Buy on Arvinas Holding Company (ARVN)
Truist Financial Analyst forecast on ARVN
Srikripa Devarakonda
Truist Financial
Truist Financial
$10
Hold
-9.09%
Downside
Reiterated
05/01/26
Arvinas gets early approval for Vepdeg, says TruistArvinas gets early approval for Vepdeg, says Truist
Citi Analyst forecast on ARVN
Yigal Nochomovitz
Citi
Citi
$21→$24
Buy
118.18%
Upside
Assigned
05/01/26
Arvinas price target raised to $24 from $21 at CitiArvinas price target raised to $24 from $21 at Citi
Morgan Stanley Analyst forecast on ARVN
Terence Flynn
Morgan Stanley
Morgan Stanley
$11
Hold
0.00%
Upside
Reiterated
03/18/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (NASDAQ: PROK), HeartFlow, Inc. (NASDAQ: HTFL) and Arvinas Holding Company (NASDAQ: ARVN)
Bank of America Securities Analyst forecast on ARVN
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$14
Hold
27.27%
Upside
Reiterated
03/18/26
Balanced View on Arvinas: Early Promise of ARV-102 Offset by Clinical, Safety, and Competitive Uncertainties Supporting a Hold Rating
Piper Sandler Analyst forecast on ARVN
Edward Tenthoff
Piper Sandler
Piper Sandler
$20
Buy
81.82%
Upside
Reiterated
03/06/26
Piper Sandler Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)
Oppenheimer Analyst forecast on ARVN
Matthew Biegler
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
02/26/26
Analysts Are Neutral on These Healthcare Stocks: Innoviva (INVA), Arvinas Holding Company (ARVN)
Stephens Analyst forecast on ARVN
Sudan Loganathan
Stephens
Stephens
$18
Buy
63.64%
Upside
Reiterated
02/25/26
Stephens Sticks to Its Buy Rating for Arvinas Holding Company (ARVN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on ARVN
Etzer Darout
Barclays
Barclays
$18→$20
Buy
81.82%
Upside
Assigned
05/13/26
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (NASDAQ: ARVN), Sarepta Therapeutics (NASDAQ: SRPT) and Surgery Partners (NASDAQ: SGRY)
H.C. Wainwright Analyst forecast on ARVN
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$18
Buy
63.64%
Upside
Reiterated
05/13/26
Arvinas Buy Rating Reiterated as Analyst Highlights Pipeline Optionality and VEPPANU Deal, Maintains $18 Price Target
Wells Fargo Analyst forecast on ARVN
Derek Archila
Wells Fargo
Wells Fargo
$15
Buy
36.36%
Upside
Assigned
05/13/26
Arvinas Holding Company (ARVN) Receives a Buy from Wells Fargo
Wedbush Analyst forecast on ARVN
Robert Driscoll
Wedbush
Wedbush
$11
Hold
0.00%
Upside
Reiterated
05/13/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (NYSE: DOCS), Arvinas Holding Company (NASDAQ: ARVN) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)
BTIG Analyst forecast on ARVN
Jeet Mukherjee
BTIG
BTIG
$16→$18
Buy
63.64%
Upside
Reiterated
05/13/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sionna Therapeutics, Inc. (NASDAQ: SION), Verrica Pharmaceuticals (NASDAQ: VRCA) and Arvinas Holding Company (NASDAQ: ARVN)
TD Cowen Analyst forecast on ARVN
Tyler Van Buren
TD Cowen
TD Cowen
―
Hold
―
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (NASDAQ: ARVN) and Sensus Healthcare (NASDAQ: SRTS)
Goldman Sachs Analyst forecast on ARVN
Paul Choi
Goldman Sachs
Goldman Sachs
$6
Sell
-45.45%
Downside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Ovid Therapeutics (NASDAQ: OVID) and Arvinas Holding Company (NASDAQ: ARVN)
Guggenheim Analyst forecast on ARVN
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$15
Buy
36.36%
Upside
Reiterated
05/01/26
Guggenheim Remains a Buy on Arvinas Holding Company (ARVN)
Truist Financial Analyst forecast on ARVN
Srikripa Devarakonda
Truist Financial
Truist Financial
$10
Hold
-9.09%
Downside
Reiterated
05/01/26
Arvinas gets early approval for Vepdeg, says TruistArvinas gets early approval for Vepdeg, says Truist
Citi Analyst forecast on ARVN
Yigal Nochomovitz
Citi
Citi
$21→$24
Buy
118.18%
Upside
Assigned
05/01/26
Arvinas price target raised to $24 from $21 at CitiArvinas price target raised to $24 from $21 at Citi
Morgan Stanley Analyst forecast on ARVN
Terence Flynn
Morgan Stanley
Morgan Stanley
$11
Hold
0.00%
Upside
Reiterated
03/18/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (NASDAQ: PROK), HeartFlow, Inc. (NASDAQ: HTFL) and Arvinas Holding Company (NASDAQ: ARVN)
Bank of America Securities Analyst forecast on ARVN
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$14
Hold
27.27%
Upside
Reiterated
03/18/26
Balanced View on Arvinas: Early Promise of ARV-102 Offset by Clinical, Safety, and Competitive Uncertainties Supporting a Hold Rating
Piper Sandler Analyst forecast on ARVN
Edward Tenthoff
Piper Sandler
Piper Sandler
$20
Buy
81.82%
Upside
Reiterated
03/06/26
Piper Sandler Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)
Oppenheimer Analyst forecast on ARVN
Matthew Biegler
Oppenheimer
Oppenheimer
―
Hold
―
Reiterated
02/26/26
Analysts Are Neutral on These Healthcare Stocks: Innoviva (INVA), Arvinas Holding Company (ARVN)
Stephens Analyst forecast on ARVN
Sudan Loganathan
Stephens
Stephens
$18
Buy
63.64%
Upside
Reiterated
02/25/26
Stephens Sticks to Its Buy Rating for Arvinas Holding Company (ARVN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arvinas Holding Company

3 Months
Edward TenthoffPiper Sandler
Success Rate
9/20 ratings generated profit
45%
Average Return
+5.73%
Copying Edward Tenthoff's trades and holding each position for 3 Months would result in 45.00% of your transactions generating a profit, with an average return of +5.73% per trade.
1 Year
Michael SchmidtGuggenheim
Success Rate
6/12 ratings generated profit
50%
Average Return
+6.63%
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +6.63% per trade.
2 Years
Yigal NochomovitzCiti
Success Rate
6/12 ratings generated profit
50%
Average Return
+22.52%
Copying Yigal Nochomovitz's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +22.52% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARVN Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
3
2
3
4
10
Buy
4
9
12
11
5
Hold
4
5
10
10
8
Sell
0
0
0
0
1
Strong Sell
0
0
0
0
0
total
11
16
25
25
24
In the current month, ARVN has received 15 Buy Ratings, 8 Hold Ratings, and 1 Sell Ratings. ARVN average Analyst price target in the past 3 months is 15.64.
Each month's total comprises the sum of three months' worth of ratings.

ARVN Financial Forecast

ARVN Earnings Forecast

Next quarter’s earnings estimate for ARVN is -$0.40 with a range of -$1.04 to $1.26. The previous quarter’s EPS was -$0.90. ARVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ARVN has Performed in-line its overall industry.
Next quarter’s earnings estimate for ARVN is -$0.40 with a range of -$1.04 to $1.26. The previous quarter’s EPS was -$0.90. ARVN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ARVN has Performed in-line its overall industry.

ARVN Sales Forecast

Next quarter’s sales forecast for ARVN is $57.45M with a range of $9.29M to $156.00M. The previous quarter’s sales results were $15.60M. ARVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ARVN has Performed in-line its overall industry.
Next quarter’s sales forecast for ARVN is $57.45M with a range of $9.29M to $156.00M. The previous quarter’s sales results were $15.60M. ARVN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ARVN has Performed in-line its overall industry.

ARVN Stock Forecast FAQ

What is ARVN’s average 12-month price target, according to analysts?
Based on analyst ratings, Arvinas Holding Company’s 12-month average price target is 15.64.
    What is ARVN’s upside potential, based on the analysts’ average price target?
    Arvinas Holding Company has 42.21% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ARVN a Buy, Sell or Hold?
          Arvinas Holding Company has a consensus rating of Moderate Buy which is based on 9 buy ratings, 6 hold ratings and 1 sell ratings.
            What is Arvinas Holding Company’s price target?
            The average price target for Arvinas Holding Company is 15.64. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $24.00 ,the lowest forecast is $6.00. The average price target represents 42.21% Increase from the current price of $11.
              What do analysts say about Arvinas Holding Company?
              Arvinas Holding Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of ARVN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.